Eliquis. Policy. covered: Eliquis is. indicated to. reduce the. therapy. Eliquis is. superior to. of 32 to. Eliquis is AMPLIFY. nonfatal. physicians.
|
|
- Janel Cameron
- 8 years ago
- Views:
Transcription
1 Eliquis (apixaban) Policy Number: Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Eliquis when it is determined to be medically necessary because the following criteria are met. When Policy Topic is covered: Coverage of Eliquis is recommendedd in those who meet thee following criteria: Food and Drug Administration (FDA)-Approved Indications 1. Nonvalvular Atrial Fibrillation (or Atrial Flutter). Approve. Eliquis is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1 In the ARISTOTLE trial, Eliquis was superior to warfarin for the primary endpoint of reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1-2 In AVERROES, Eliquis showed a significant reduction in stroke and systemic embolism compared with aspirin in a group of patients with nonvalvular atrial fibrillation who were thought not to be candidates for warfarin therapy. 1,3 The 2011 guidelines for atrial fibrillation from the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the Heart Rhythm Society (HRS) recommend patients with atrial flutter follow the antithrombotic therapy decisionss that are in place for atrial fibrillation. 10 The decision to adopt the criteria was based on the professional opinion of specialist physicians. 2. Prophylaxis of Deep Vein Thrombosis (DVT) in Patients Undergoing Hip or Knee Replacement Surgery. Approve for 60 days. Eliquis is indicated for the prophylaxis of DVT, which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1 In patients undergoing elective hip surgery, Eliquis 2.5 mg BID was superior to enoxaparinn 40 mg SC QD (treatment duration of 32 to 38 days) in reducing total VTE/all-cause death (P < ). 1 In patients undergoing knee replacement surgery (treatment duration 10 to 14 days), Eliquis 2. 5 mg BID had similar outcomes as enoxaparin 30 mg SC Q 12 hours and it was superior to enoxaparin 40 mg SC QD (P < ). Allowing 60 days of therapy should be a sufficient time frame to allow for an adequatee therapy duration in both scenarios. The decision to adopt the criteria was based on the professional opinion of specialist physicians. 3. Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE), Treatment. Approve. Eliquis is indicated for the treatment of DVT and for the treatment of PE. 1 After approximately 6 months of therapy, Eliquis was demonstrated to bee noninferiorr to enoxaparin/warfarin in the AMPLIFY study for the primary endpoint of recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death. 1,7 The decision to adopt the criteria was based on the professional opinion of specialist physicians
2 4. Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) to Reduce the Risk of Recurrence. Approve. Eliquis is indicated to reduce the risk of recurrent DVT or PE following initial therapy. In the AMPLIFY-EXT trial, which involved patients who had previously been successfully treated with anticoagulant therapy for DVT and/or PE, Eliquis was superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE), or all-cause death. The decision to adopt the criteria was based on the professional opinion of specialist physicians Other Uses with Supportive Evidence 5. Treatment or Prevention of Other Thromboembolic-Related Indications not Addressed in the Conditions Not Recommended for Approval Section below (e.g., extended thromboprophylaxis in medically-ill patients, extended treatment for patients with a prior venous thromboembolism). Approve if the patient meets ONE of the following criteria (a, b or c): a) Patient has tried one of the following therapies for the condition: warfarin, Xarelto (rivaroxaban tablets), Pradaxa (dabigatran capsules), Savaysa (edoxaban tablets,) fondaparinux injection, or a low molecular weight heparin (LMWH) product (e.g., enoxaparin injection, Fragmin [dalteparin injection]); OR b) Patient is unable to take one of the medications listed above (i.e., warfarin, Xarelto, Pradaxa, Savaysa, fondaparinux injection or a LMWH) for the condition due to ONE of the following reasons: i. allergic, immunologic or inherited disorders; OR ii. adverse effects (e.g., major organ toxicities, major bleeding); OR iii. the patient has experienced ineffectiveness of anticoagulation therapy in a prior setting; OR iv. the patient has drug-drug interactions that cannot be managed (warfarin); OR v. the patient lacks access to proper monitoring (warfarin); OR vi. the patient has experienced prior heparin-induced thrombocytopenia (HIT) or heparininduced thrombocytopenia and thrombosis (HITT) [fondaparinux injection and LMWH]; OR vii. the patient is unable to perform injections or have injections administered to them (fondaparinux injection and LMWH); OR c) The patient has been started on Eliquis for the treatment of an acute thromboembolic condition. Note: If the patient has a history of an ACS or coronary artery disease (CAD) (excluded indications), but is requesting Eliquis for a non-acs or non-cad condition, approval can be considered if criteria are met. Eliquis has been studied in other conditions that require anticoagulant therapy (e.g., as an extended treatment for patients who have completed therapy for DVT or PE, and for thromboprophylaxis in medically-ill patients). 4,8 Many other medications have been determined to be effective in the treatment of various thromboembolic conditions, as noted in the 2012 American College of Chest Physicians (ACCP) evidence-based clinical practice guidelines for antithrombotic therapy and the prevention of thrombosis. 11 The criteria will allow for continuation of therapy for patients who have been started on Eliquis for an acute thromboembolic condition. In the professional opinion of specialist physicians reviewing the data, we have adopted these criteria. 6. Patients Currently Receiving Eliquis Therapy. For patients started on Eliquis, if there is insufficient information available to make a determination regarding approval OR if the prescribing physician or a representative of the physician cannot be contacted OR if the patient requires time to initiate another therapy (e.g., warfarin, LMWH), a short-term supply of Eliquis for up to 14 days can be approved. (In the professional opinion of specialist physicians we have adopted this criterion).
3 When Policy Topic is not covered: Eliquis has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for noncoverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.) 1. Use After an Acute Coronary Syndrome (ACS) (e.g., unstable angina, non-st elevation myocardial infarction [MI], or ST elevation MI) to Reduce the Potential for Thrombotic Events (e.g., cardiovascular [CV] death, MI, or stroke). The APPRAISE-2 trial was terminated after it was found that the addition of Eliquis to antiplatelet therapy in high-risk patients after an ACS event increased the number of major bleeding events without a significant reduction in recurrent ischemic events. 10 Other alternative, proven, effective, established therapies that are detailed in nationallyrecognized guidelines are available for those who have experienced an ACS (e.g., heparin, aspirin, clopidogrel, Effient [prasugrel tablets], Brilinta [ticagrelor tablets], and LMWHs) In the professional opinion of specialist physicians reviewing the data, we have adopted these criteria. 2. Primary or Secondary Prevention of Coronary Artery Disease (CAD). Eliquis is not indicated for this condition and data are limited. Many other proven, established medications are used for patients with CAD. In the professional opinion of specialist physicians reviewing the data, we have adopted these criteria. 3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available. Considerations Eliquis requires prior authorization through the pharmacy services department. This Blue Cross and Blue Shield of Kansas City policy Statement was developed using available resources such as, but not limited to: Hayes Medical Technology Directory, Food and Drug Administration (FDA) approvals, Facts and Comparisons, National specialty guidelines, Local medical policies of other health plans, Medicare (CMS), Local providers. Description of Procedure or Service Eliquis is a factor Xa inhibitor anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1 For this indication, the recommended dose for most patients is 5 mg twice daily (BID). The recommended dose of Eliquis is 2.5 mg BID in nonvalvular atrial fibrillation for patients with any two of the following characteristics: age 80 years; body weight 60 kg; and serum creatinine 1.5 mg/dl. Eliquis is also indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. For this indication, the recommended dose of Eliquis is 2.5 mg taken orally BID. The initial dose should be taken 12 to 24 hours after surgery. In patients undergoing hip replacement surgery, the recommendation duration of treatment is 35 days and in patients undergoing knee replacement surgery the recommended duration of treatment is 12 days. Eliquis is also indicated for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. For the treatment of DVT and PE, the recommended dose is 10 mg BID for 7 days, followed by 5 mg BID. For the reduction in the risk of recurrent DVT and PE following initial therapy, the initial dose is 2.5 mg BID. Also, when Eliquis is given with medications that are strong dual inhibitors of cytochrome P450 (CYP) and P-glycoprotein (P-gp) [e.g., ketoconazole, itraconazole], the Eliquis recommended dose is 2.5 mg BID. The most common adverse events (AEs) with Eliquis are related to bleeding. 1
4 Rationale Clinical Efficacy Atrial Fibrillation Two multinational, double-blind, double-dummy, randomized, published trials assessed the efficacy and safety of Eliquis in patients with nonvalvular atrial fibrillation. The ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events) trial compared Eliquis with warfarin (n = 18,201). 1-2 Eliquis 5 mg BID was superior to warfarin for the primary endpoint of reducing the risk of stroke and systemic embolism (1.27% per year for Eliquis vs. 1.60% per year for warfarin; P = 0.01). Eliquis also led to a significantly lower rate of all-cause death compared with warfarin (P = 0.046). The AVERROES trial compared Eliquis with aspirin in patients who were not candidates for warfarin therapy (n = 5,599). 1,3 Patients were randomized to Eliquis 5 mg BID (or 2.5 mg BID) or aspirin 81 to 324 mg once daily (QD). The trial was stopped early on the basis of a prespecified interim analysis demonstrating a significant reduction in stroke and systemic embolism for patients randomized to Eliquis compared with aspirin (1.62% per year with Eliquis vs. 3.63% per year with aspirin; P < ). 1,3 The mean follow-up was 1.1 years. 3 Prophylaxis of DVT Following Hip or Knee Replacement Surgery The effectiveness of Eliquis was derived from the ADVANCE 1,4-6 (Apixiban Dose orally Vs. ANtiCoagulant with Enoxaparin)-1, ADVANCE-2, and ADVANCE-3 trials involving adults undergoing elective hip (ADVANCE-3) 6 or knee (ADVANCE-2 and ADVANCE-1) 4-5 replacement surgery. In total, 11,659 patients were randomized in three double-blind, multinational studies. 1,4-6 In ADVANCE-3, 5,407 patients undergoing hip replacement surgery were randomized to receive either Eliquis 2.5 mg BID or enoxaparin 40 mg subcutaneously (SC) QD; treatment duration was 32 to 38 days. 1,6 In ADVANCE-3 involving patients who underwent elective hip replacement surgery, the percentage of patients with events (total venous thromboembolism [VTE]/all-cause death) was 3.86% for patients (n = 74/1,917) receiving enoxaparin 40 mg SC QD vs. 1.39% for patients (n = 27/1,949) in the Eliquis 2.5 mg BID group (P < ). 1,7 In patients undergoing elective knee replacement surgery, Eliquis 2.5 mg BID was compared with enoxaparin 40 mg SC QD (ADVANCE-2, n = 3,057) 1,5 or enoxaparin 30 mg SC every 12 hours (ADVANCE-1, n = 3,195). 1,4 Treatment duration in both ADVANCE-2 and ADVANCE-1 was 10 to 14 days. In the ADVANCE-1 group, the percentage of patients undergoing elective knee surgery with events during the 12-day treatment period (total VTE/all-cause death) was 8.85% for patients given enoxaparin 30 mg QD every 12 hours (n = 100/1,130) compared with 8.99% of patients given Eliquis 2.5 mg BID (n = 104/1,157). 1,4 In the ADVANCE-2 group, the percentage of patients undergoing elective knee surgery with events during the 12-day treatment period (total VTE/allcause death) was 24.37% for patients given enoxaparin 40 mg QD (n = 243/997) compared with 15.06% of patients given Eliquis 2.5 mg BID (n = 147/976) [P < ]. 1,5 Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT and PE The effectiveness of Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following 6 to 12 months of anticoagulant treatment was assessed in the AMPLIFY (Apixaban after the initial Management of PuLmonary embolism and deep vein thrombosis with First-line therapy and AMPLIFY-EXT trial (EXtended Treatment) trials. 1,7-8 Both studies were randomized, parallel-group, double-blind trials involving patients with symptomatic proximal DVT and/or symptomatic PE. In AMPLIFY (n = 5,244) patients were given Eliquis 10 mg BID for 7 days, followed by Eliquis 5 mg BID for 6 months, or enoxaparin 1 mg/kg BID SC for at least 5 days, followed by warfarin for 6 months. After a mean of approximately 153 days, Eliquis was noninferior to enoxparin/warfarin in the primary endpoint of recurrent symptomatic VTE or VTE-related deaths over 6 months (2.3% with Eliquis vs. 2.7% with enoxaparin/warfarin). 1,7 The AMPLIFY-EXT trial involved patients (n = 2,482) who had been treated for DVT and/or PE for 6 to 12 months with anticoagulant therapy without experiencing a recurrent event and were randomized to Eliquis 2.5 mg BID, Eliquis 5 mg BID, or placebo for 12 months. 1,8 Approximately one-third of patients had been in the AMPLIFY trial before enrollment in AMPLIFY-EXT. 1 After almost 1 year of follow-up, Eliquis was superior to placebo as the primary endpoint of recurrent VTE or all-cause death occurred in 3.8%, 4.2% and 11.6% of patients assigned to Eliquis 2.5 mg BID, Eliquis 5 mg BID, or placebo, respectively.
5 Other Data Eliquis has been used off-label for other conditions requiring antithrombotic therapy. The ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial investigated the use of Eliquis vs. enoxaparin in medically-ill patients in an extended thromboprophylaxis setting. 9 The APPRAISE (APixaban for PRevention of Acute ISchemic Events)-2 trial was terminated prematurely after it was found that the addition of Eliquis to antiplatelet therapy in high-risk patients after an acute coronary syndrome (ACS) increased the number of major bleeding events without a significant reduction in recurrent ischemic events. 10 References: 1. Eliquis tablets [prescribing information]. Princeton, NJ: Bristol-Myers Squibb and New York, NY: Pfizer Inc; August Granger CB, Alexander JH, McMurray JJV, et al, for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11): [Supplementary appendix]. 3. Connolly SJ, Eikelboom J, Joyner C, et al, for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9): [Supplementary appendix]. 4. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361: Lassen MR, Raskob GE, Gallus A, et al, and the ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized, doubleblind trial. Lancet. 2010;375: Lassen MR, Gallus A, Raskob GE, et al, for the ADVANCE-3 investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26): Agnelli G, Buller HR, Cohen A, et al, for the AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9): Agnelli G, Buller HR, Cohen A, et al, for the AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8): Goldhaber SZ, Leizorovicz A, Kakkar AK, et al, for the ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365: Alexander JH, Lopes RD, James S, et al, for the APPRAISE-2 investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8): January CT, Wann LS, Alpert JS, et al AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the heart rhythm society. Circulation April 10 [Epub ahead of print]. Available at Accessed on September 19, Guyatt GH, Akl EA, Crowther M, et al., for the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9 th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S-47S. 13. O Gara PT, Kushner FG, Ascheim DD, et al, American College of Cardiology Foundation/American Heart Association Task Force on Practice guidelines ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e Available at Accessed on September 19, Jneid H, Anderson JL, Wright S, et al ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-st elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of
6 Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;126: Available at Access on September 19, Billing Coding/Physician Documentation Information NA Additional Policy Key Words Policy Number: Related Topics N/A Policy Implementation/Update Information 06/2014 New Policy titled Eliquis (apixaban) 07/2015 Annual review- Added new indications regarding treatment of deep vein thrombosis or pulmonary embolism and for the reduction in the risk of recurrent deep vein thrombosis or pulmonary embolism; For the treatment or prevention of other thromboembolic-related indications, Savaysa was added to the list of multiple other agents (e.g., oral anticoagulants and heparin-type products) for which the patient is recommended to have tried one of prior to approval. This Medical Policy is designed for informational purposes only and is not an authorization, an explanation of benefits, or a contract. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there is any exclusion or other benefit limitations applicable to this service or supply. Medical technology is constantly changing and Blue Cross and Blue Shield of Kansas City reserves the right to review and revise medical policy. This information is proprietary and confidential and cannot be shared without the written permission of Blue Cross and Blue Shield of Kansas City.
xaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.
Xarelto (rivarox xaban) Policy Number: 5.01.575 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Xarelto when it is determined to be medically necessary
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationThrombosis and Hemostasis
Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationPrior Authorization Guideline
Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204
More informationMedication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationRandomized, double-blind, parallel-group, multicenter, doubledummy
ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)
More informationBayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationReview of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain
Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview
More informationDabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationOut with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
More informationThe New Kids on the Block: Oral Anticoagulants
The New Kids on the Block: Oral Anticoagulants Lauren E. Odum, PharmD, BCPS Clinical Assistant Professor UMKC School of Pharmacy at MU April 11, 2014 Objectives Be able to Understand the major trials leading
More informationDATE: 06 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationWOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationCost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip
Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Replacement or Total Knee Replacement National Centre
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationInvestor News. Not intended for U.S. and UK media
Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationTherapeutic Class Overview Oral Anticoagulants
Therapeutic Class Overview Oral Anticoagulants Therapeutic Class Overview/Summary: The oral anticoagulants, dabigatran etexilate mesylate (Pradaxa ), rivaroxaban (Xarelto ), and warfarin (Coumadin, Jantoven
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationEINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012
EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors
News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More informationRole of Apixaban (Eliquis) in the Treatment And Prevention of Thromboembolic Disease
DrUG FOrECAST Role of Apixaban (Eliquis) in the Treatment And Prevention of Thromboembolic Disease Aliaksandr Budovich; Olga Zargarova; and Anna Nogid, BS, PharmD, BCPS INTRODUCTION From the 1940s through
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationTHE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS Ingo Ahrens, Christoph Bode Cardiology and Angiology I, Heart Center Freiburg University, Freiburg,
More informationRivaroxaban. Practical Experience in the Cardiology Setting. Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013
Rivaroxaban Practical Experience in the Cardiology Setting Bernhard Meier, Bern Bayer Satellite Symposium Cardiology Update Davos February 11, 2013 Overview of phase III clinical trials of new oral anticoagulants
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationThe 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012
The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received
More informationDisclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More information2. Background This indication of rivaroxaban had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationAbbreviated Class Update: Anticoagulants. Month/Year of Review: July 2014 End date of literature search: June 2014
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationCardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationThe Anti coagulated Patient: The Cardiologist s View. February 28, 2015
The Anti coagulated Patient: The Cardiologist s View February 28, 2015 Conflicts Dr. McMurtry has no conflicts to disclose. CanMeds Medical Expert (as Medical Experts, physicians integrate all of the CanMEDS
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationBayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of
More informationInvestor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationNew Oral Anticoagulant (Rivaroxaban [Xarelto])
TABLE OF CONTENTS New Oral Anticoagulant (Rivaroxaban [Xarelto]) 1-2 New Antiplatelet (Ticagrelor [Brilinta]) 2-3 Update on Dabigatran (Pradaxa) Safety and Use at UIMCC 3-4 What Methods are Available for
More informationAre there sufficient indications for switching to new anticoagulant agents
Are there sufficient indications for switching to new anticoagulant agents Meyer Michel Samama et Gregoris Gerotziafas Groupe Hémostase-Thrombose Hôtel-Dieu, Hôpital Tenon, Paris & Biomnis Ivry/seine,
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationNew Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET Departments of Gastroenterology and Hepatology,
More informationIntroduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
More informationSummary Review. Newer Oral Anticoagulant Drugs
Summary Review Newer Oral Anticoagulant Drugs Final Original Report January 2013 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of reports is to make
More informationTo provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.
More informationOral Anticoagulant - Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), and Xarelto (rivaroxaban) Quantity Limit Program Summary
Oral Anticoagulant - Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), and Xarelto (rivaroxaban) Quantity Limit Program Summary This program applies to FlexRx open, FlexRx closed, GenRx open,
More informationGruppo di lavoro: Malattie Tromboemboliche
Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationComparison of Oral Anticoagulants
PL Detail-Document #300601 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2014 Comparison of Oral
More informationA PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
More informationBayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationUpdate on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More information9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban
Identify the FDA approved direct oral anticoagulants (DOACs) Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services Distinguish the differences in the dosing of DOACs for various indications Describe
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationRivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery
for preventing venous thromboembolism after hip or knee replacement surgery (riv-ah-rocks-ah-ban) Summary Rivaroxaban is an oral anticoagulant and the first direct factor Xa inhibitor. Rivaroxaban has
More informationHot Line Session at European Society of Cardiology (ESC) Congress 2014:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily
More informationPharmacological prophylaxis for venous thromboembolism
Pharmacological prophylaxis for venous thromboembolism Essence of this ArticleFor more than 20 years, routine preventive anticoagulant therapy has been the standard of care after major orthopaedic surgery.
More information